Berger AK, et al. - A retrospective analysis was performed of patients with advanced pancreatic cancer under palliative first-line treatment with FOLFIRINOX at the National Center for Tumor Diseases, Heidelberg, to evaluate efficacy and toxicity in academic practice, especially focusing on older patients. In patients with pancreatic cancer, the researchers did not recommend withholding the treatment with the FOLFIRINOX protocol from patients solely based on their chronological age. However, it ought to be based on the patient’s performance status and comorbidities.